title: Biodistribution of boron after intravenous 4-dihydroxyborylphenylalanine-fructose (BPA-F) infusion in meningioma and schwannoma patients: A feasibility study for boron neutron capture therapy.
abstract: We studied the uptake of boron after 100 mg/kg BPA infusion in three meningioma and five schwannoma patients as a pre-BNCT feasibility study. With average tumour-to-whole blood boron concentrations of 2.5, we discuss why BNCT could, and probably should, be developed to treat severe forms of the studied tumours. However, analysing 72 tumour and 250 blood samples yielded another finding: the plasma-to-whole blood boron concentrations varied with time, suggesting that the assumed constant boron ratio of 1:1 between normal brain tissue and whole blood deserves re-assessment.
authors: Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; The Research Institute of the Finnish Economy, Helsinki, Finland. Electronic address: martti.kulvik@etla.fi.
authors: Martti
authors: M
authors: Kulvik
authors: Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
authors: Merja
authors: M
authors: Kallio
authors: Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland; TUKES, Finnish Safety and Chemicals Agency, Helsinki, Finland.
authors: Juha
authors: J
authors: Laakso
authors: Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
authors: Jyrki
authors: J
authors: Vähätalo
authors: Aalto University School of Economics, Helsinki, Finland.
authors: Raine
authors: R
authors: Hermans
authors: HUCH Pharmacy, Helsinki University Central Hospital, Helsinki, Finland.
authors: Eija
authors: E
authors: Järviluoma
authors: Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland.
authors: Anders
authors: A
authors: Paetau
authors: HUCH Pharmacy, Helsinki University Central Hospital, Helsinki, Finland.
authors: Merja
authors: M
authors: Rasilainen
authors: Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
authors: Inkeri
authors: I
authors: Ruokonen
authors: Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland.
authors: Matti
authors: M
authors: Seppälä
authors: Neurosurgery, Institute of Clinical Medicine, Faculty of Medicine, University of Kuopio, Kuopio, Finland.
authors: Juha
authors: J
authors: Jääskeläinen
mesh_terms: D000328:Adult; D000368:Aged; D001895:Boron / Q000493:pharmacokinetics*; D001896:Boron Compounds / Q000008:administration & dosage*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000532:radiotherapy*; D005240:Feasibility Studies; D005260:Female; D005632:Fructose / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008579:Meningioma / Q000532:radiotherapy*; D008875:Middle Aged; D009442:Neurilemmoma / Q000532:radiotherapy*; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014018:Tissue Distribution; D055815:Young Adult
chemical_list: C436045:4-dihydroxyborylphenylalanine; D001896:Boron Compounds; D005632:Fructose; D010649:Phenylalanine; D001895:Boron
keywords: BNCT; Meningioma; NF2; Schwannoma